Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 517 Bevacizumab 488 Carboplatin 424 pembrolizumab 388 Paclitaxel 385 Gemcitabine 372 Cisplatin 366 Docetaxel 323 Rituximab 316 Radiotherapy 296 Nivolumab 247 Doxorubicin 243 Dexamethasone 240 Fluorouracil 225 Capecitabine 214 Oxaliplatin 211 Erlotinib Hydrochloride 206 fludarabine phosphate 201 Etoposide 188 Cetuximab 186 Lenalidomide 177 Pemetrexed 176 Bortezomib 174 Trastuzumab 173 Filgrastim 171 fludarabine 166 Prednisone 166 Leucovorin 166 Cytarabine 166 Irinotecan 161

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Has results × pralsetinib × Clear all

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡